VIEW ALL NEWS Mar 27, 2025 BioXcel Therapeutics Reports Financial Results for the Fourth Quarter and Full Year 2024VIEW RELEASE Mar 11, 2025 BioXcel Therapeutics Strengthens Cash Position to Advance SERENITY At-Home Pivotal Phase 3 Safety Trial for Acute Treatment of Agitation Associated with Bipolar...
BioXcel Therapeutics Strengthens Cash Position to Advance SERENITY At-Home Pivotal Phase 3 Safety Trial for Acute Treatment of Agitation Associated with Bipolar Disorders or SchizophreniaVIEW RELEASE Stock Information BioXcel Therapeutics, Inc. May 15, 2025 04:00 PM MARKET/SYMBOL Nasdaq: BTAI PRICE ...
NEWS 19 April 2022 BioXcel Therapeutics Announces Formation of OnkosXcel Therapeutics... BioXcel Featured in Fierce Biotech The recent uptick in interest in drug repurposing, the popularity of which ebbs and flows, could give the team a tailwind.. ...
BioXcel Therapeutics公布2024年第三季度财报BTAI 0.28% 2024年10月31日,BioXcel Therapeutics, Inc. (NASDAQ: BTAI) 公布了第三季度财务业绩,并提供了临床试验的最新进展,包括其BXCL501药物候选者的进展情况。首席执行官Vimal Mehta博士和首席财务官Richard Steinhart主持了讨论,重点介绍了两项关键的III期试验的启动...
BioXcel Therapeutics股价触及52周新低1.72美元 Investing.com — BioXcel Therapeutics Inc.股价遭遇重挫,跌至52周新低1.72... 提供者Investing.com •2025年4月04日 BioXcel Therapeutics启动场内股权融资计划 Investing.com — BioXcel Therapeutics, Inc. (NASDAQ:BTAI),一家... 提供者Investing.com •2025年4...
2022年4月6日,BioXcel Therapeutics公司宣布,使用BioXcel的AI平台开发的药物Igalmi获FDA批准。Igalmi (dexmedetomidine,右美托咪啶) 是一种舌下膜剂,旨在减少被诊断为双相情感障碍或精神分裂症患者的躁动发作,易于使用、可以快速起效。 BioXcel将此称为AI的胜利。
BioXcel Therapeutics (NASDAQ:BTAI) will implement a 1-for-16 reverse stock split of its common stock on February 7, 2025. The reverse stock split is part of the company's plan to regain compliance wit...
BioXcel Therapeutics, Inc. (Nasdaq: BTAI), today announced results from its ongoing Phase 2 trial of BXCL701, the Company's investigational, oral innate immunity activator, in metastatic castration-resistant prostate cancer (mCRP...
BioXcel Therapeutics公司(BioXcel Therapeutics Inc.,简称BioXcel,NASDAQ:BTAI)是一家临床阶段生物制药公司,致力于利用人工智能的方法开发神经学和肿瘤免疫学领域相关转化药物。该公司今天公布其BXCL501的1b/2期概念验证研究RELEASE的顶线结果。BXCL501是该公司专有的、口服溶解的右旋美托咪啶薄膜制剂,用于治疗阿片类依赖...
BioXcel Therapeutics, Inc. (“BTI” or “Company”) (Nasdaq: BTAI), a clinical-stage biopharmaceutical company utilizing artificial intelligence to identify improved therapies in neuroscience and immuno-oncology, today announced it will host a conference call and...